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Original Articles
Prognostic Value of Routine Cardiac Magnetic Resonance
Assessment of Left Ventricular Ejection Fraction and
Myocardial Damage
An International, Multicenter Study
Igor Klem, MD; Dipan J. Shah, MD; Richard D. White, MD; Dudley J. Pennell, MD;
Albert C. van Rossum, MD, PhD; Matthias Regenfus, MD; Udo Sechtem, MD;
Paulo R. Schvartzman, MD, PhD; Peter Hunold, MD; Pierre Croisille, MD, PhD;
Michele Parker, RN, MS; Robert M. Judd, PhD; Raymond J. Kim, MD
Background—Cardiac magnetic resonance (CMR) is considered the reference standard for assessment of left ventricular
ejection fraction (LVEF) and myocardial damage. However, few studies have evaluated the relationship between CMR
findings and patient outcome, and of these, most are small and none multicenter. We performed an international,
multicenter study to assess the prognostic importance of routine CMR in patients with known or suspected heart disease.
Methods and Results—From 10 centers in 6 countries, consecutive patients undergoing routine CMR assessment of LVEF
and myocardial damage by cine and delayed-enhancement imaging (DE-CMR), respectively, were screened for
enrollment. Clinical data, CMR protocol information, and findings were collected at all sites and submitted to the data
coordinating center for verification of completeness and analysis. The primary end point was all-cause mortality. A total
of 1560 patients (age, 5914 years; 70% men) were enrolled. Mean LVEF was 4518%, and 1049 (67%) patients had
hyperenhanced tissue (HE) on DE-CMR indicative of damage. During a median follow-up time of 2.4 years
(interquartile range, 1.2, 2.9 years), 176 (11.3%) patients died. Patients who died were more likely to be older
(P0.0001), have coronary disease (P0.004), have lower LVEF (P0.0001), and have more segments with HE
(P0.0001). In multivariable analysis, age, LVEF, and number of segments with HE were independent predictors of
mortality. Among patients with near-normal LVEF (50%), those with above-median HE (4 segments) had reduced
survival compared to patients with below- or at-median HE (P0.02).
Conclusions—Both LVEF and amount of myocardial damage as assessed by routine CMR are independent predictors of
all-cause mortality. Even in patients with near-normal LVEF, significant damage identifies a cohort with a high risk for
early mortality. (Circ Cardiovasc Imaging. 2011;4:610-619.)
Key Words: magnetic resonance imaging  ventricular ejection fraction  myocardial infarction  prognosis
Cardiac magnetic resonance (CMR) has become an im-portant diagnostic tool in clinical practice,1,2 which may
be largely attributed to the robust implementation of cine- and
delayed contrast-enhancement CMR (DE-CMR) techniques.
Cine-CMR with quantitative analysis is considered the
reference standard for assessment of morphology and left
ventricular ejection fraction (LVEF).3,4 LVEF is one of the
most important predictors of survival in patients with
coronary artery disease (CAD),5 heart failure,6 and cardio-
myopathy.7,8 Previous studies establishing the prognostic
importance of LVEF used traditional modalities such as
echocardiography,5,7,9 radionuclide ventriculography,6,10
and ECG-gated single-photon emission CT.11 To date, few
CMR investigations have evaluated the relation between
CMR-based LVEF measurement and prognosis, and of
these, none were multicenter.12–18 The assessment of the
prognostic significance of CMR-based LVEF is important
because the agreement of LVEF measurements in the same
patient assessed with different modalities is moderate
at best.19
Clinical Perspective on p 619
Similarly, DE-CMR is considered the reference standard
for the assessment of myocardial damage (necrosis, scar).20,21
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This technique offers high-spatial resolution imaging of
pathophysiological processes related to myocardial infarction
(MI)22–25 or nonischemic heart disease12,26–29 that was previ-
ously achievable only by postmortem histopathological eval-
uation. Given its advantages, DE-CMR increasingly is being
used as a surrogate end point in clinical trials that test new
therapies for acute MI.30 However, similar to cine-CMR, of
the few studies that have assessed the prognostic importance
of DE-CMR, most were small, and none were multicenter.
The purpose of the present study was to examine the
prognostic value of a routine CMR assessment of LVEF and
myocardial damage in a broad, real-life population enrolled
consecutively from several centers.
Methods
Study Design
This observational, multicenter study was funded in part by Siemens
Medical Solutions (Erlangen, Germany), which did not have access
to the data. Data collection and analysis were independently per-
formed at Duke University Medical Center, which served as the data
coordinating center (DCC). The lead investigators had full access to
the data and wrote the article without need for approval by the
sponsor. The participating centers were located in the United States
(3), Europe (England, 1; Germany, 3; France, 1; The Netherlands, 1),
and South America (Brazil, 1). Among the 10 sites, 7 were university
hospitals, and 3 were tertiary cardiovascular care centers. Institu-
tional Review Board approval was received at each center according
to local regulations. In most centers (n8), data were collected
retrospectively, and deidentified data were submitted to the DCC.
Therefore, informed consent was waived by the Institutional Review
Board. In 2 centers, patients were enrolled prospectively (n646),
and written informed consent was obtained from all patients.
Patients and Data Collection
An outline of patient screening, enrollment, and data collection is
shown in Figure 1. At each cardiovascular MRI center, consecutive
patients of either gender undergoing an MRI (either cardiac, vascu-
lar, or both) were screened. All patients who completed a routine
cardiac study for assessment of both function and myocardial
damage (with a complete stack of cine and DE imaging) and with at
least 1 year of follow-up (unless death occurred within the follow-up
period) were enrolled.
The participating centers decided a priori on the study design and
a limited number of data items to be collected by each site. A
standard data collection form, including demographic information, a
targeted medical history, CMR protocol information and findings,
and follow-up information, was completed for each patient. The
medical history was obtained by review of medical records by the
local study investigators and was limited to determining the presence
or absence of the following: known or suspected heart disease,
known or suspected CAD, and MI 7 days before the index CMR
scan. Follow-up status was ascertained by review of medical records,
interrogation of the Social Security Death Index for US sites, and
physician and patient/family telephone contact. The prespecified
primary end point was all-cause mortality. Hard copies of the data
collection forms were stored at each study site. All data except for
the patient identifiers were submitted electronically to the DCC,
where their completeness was verified. All submitted patients with
complete data were included in the final analysis.
Cardiac Magnetic Resonance
Imaging Protocol
Images were acquired on clinical 1.5-T Siemens scanners using
phased-array receiver coils according to the routine scan protocol at
each site. A typical protocol was as follows: First, localizers were
acquired to identify the cardiac position and the standard long- and
short-axis of the heart, and then cine images were acquired in
multiple short-axis (to cover the LV from base to apex) and 3
long-axis views (2, 3, and 4 chamber) using a steady-state free-
precession (SSFP) sequence.31 For DE-CMR, an inversion-recovery
Figure 1. Outline of patient enrollment and data collection. The
first 3 steps occurred at the individual participating centers and
involved patient screening, data collection from enrolled
patients, and data submission after deidentification. Steps 4 and
5 included data verification and analysis at the DCC. At each
cardiovascular MRI center, consecutive patients of either gender
undergoing an MRI (either cardiac, vascular, or both) were
screened. All patients screened were subsequently enrolled
unless they had only a vascular study (no cardiac imaging),
had an incomplete cardiac study (eg, cine imaging without
DE-CMR), did not have a full year of follow-up, or did not give
informed consent (at sites enrolling patients prospectively). After
submission of enrolled patient data to the DCC, 22 patients
were excluded because of withdrawal of consent (n1), incom-
plete CMR protocol information or CMR findings (n19), or
incomplete follow-up data (n2). CMR indicates cardiac mag-
netic resonance; DCC, data coordinating center; DE, delayed
enhancement.
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pulse-sequence for T1 weighting was required,32 with either an SSFP
or gradient-recalled echo (GRE) data readout, and images were
obtained 10 to 20 minutes after gadolinium contrast injection
(0.1–0.2 mmol/kg) in the identical views as cine-CMR.
Image Analysis
The study site investigators analyzed images on locally available
workstations and were blinded to follow-up data. The LVEF was
determined on cine images either by planimetry of endocardial and
epicardial contours in both diastole and systole or by a visual
assessment providing a numeric estimate of LVEF following each
site’s institutional protocol (ie, following the same process used for
their routine clinical interpretations). For the assessment of regional
wall motion, the standard American Heart Association 17-segment
model was used33 with a 5-point scoring system (0normal;
1mild, moderate hypokinesis; 2severe hypokinesis; 3akinesis;
4dyskinesis). To provide an estimate of the extent of regional wall
motion abnormalities, a mean wall motion score was computed by
summation of all scores divided by the number of segments.
Similarly, the presence and location of hyperenhanced tissue (HE) on
DE-CMR, which was assumed to represent irreversibly damaged
myocardial tissue,12,25 was assessed by visual inspection using the
standard 17-segment model.33 At the DCC, regional enhancement
was classified according to the presence or absence of HE within
each segment. Study investigators had been instructed to score HE
on a 5-point scale (0no hyperenhancement; 11%–25%; 226%–
50%; 351%–75%; 476%–100%)22; however, after data collec-
tion, it became clear that the 5-point scale was used to index the
spatial area of HE by some centers and the maximum transmurality
of HE at any given point by other centers. Thus, for the purpose of
data analysis performed at the DCC, the total LV amount of HE was
expressed simply as the number of segments with any HE (ie, for
each patient, HE score could range from 0–17).
Statistical Analysis
Continuous data are presented as meanSD or in cases where the
distribution was not normal, as median and interquartile range.
Two-sample t tests were used to compare mean values of continuous
data between 2 groups. Chi-square tests were used to compare
discrete data between groups. Based on the observed median value of
number of segments with HE, the study population was divided into
2 groups, and the survival of both cohorts was further analyzed
according to the Kaplan–Meier method. The significance of differ-
ences in event rates between groups was assessed with the Cox
regression analysis. Multivariable Cox regression analysis was
performed using stepwise regression techniques, including all clini-
cal variables (that were not collinear) and the best CMR covariates
(see Table 1 for covariates) to identify the best overall model.
Because the unadjusted relationship between the number of segments
with HE and outcomes was nonlinear, a transformation (segments
with HE2) was implemented. The incremental prognostic value of
CMR variables was examined by the change in likelihood ratio 2 of
the model after addition of each candidate variable. To account for
possible differences according to study site, it was included as a
covariate in all multivariable analyses. Results were expressed as
hazard ratios with associated 95% CIs. The relationships between
mortality and the categories of LVEF and segments with HE were
assessed using Cox regression analysis adjusted for site and age.
Based on these models, predicted event rates were calculated at a
fixed time point of 2 years. All statistical tests were 2 tailed, and
P0.05 was regarded as significant.
Results
Study Population
Patients undergoing an MRI study between September 1999
and January 2004 were screened for study enrollment at 10
centers (Figure 1). All patients screened were subsequently
enrolled unless they only had a vascular study (no cardiac
imaging), had an incomplete cardiac study (eg, cine imaging
without DE-CMR), did not have a full year of follow-up, or
did not give informed consent (at sites enrolling patients
prospectively). Data on 1582 patients who met inclusion
criteria were submitted to the DCC (the last data collection
form was submitted in June 2006). After data submission, 22
patients were excluded because of incomplete CMR data
(n19), unknown follow-up date (n2), or withdrawal of
patient consent (n1). Each site contributed on average
156109 patients (range, 50–346); 925 patients were from
US sites, 561 were from Europe, and 74 were from Brazil. The
most frequently used pulse sequence for DE-CMR was the 2D
segmented inversion-recovery GRE sequence, which was used
in 1431 (92%) studies. Rarely, other pulse sequences were used,
including the 2D real-time, subsecond SSFP sequence34 in 93
(6%) studies followed by the 3D segmented GRE sequence in 22
(1.4%), 2D segmented SSFP sequence in 7 (0.4%), and the 2D
subsecond GRE sequence in 6 (0.4%).
The general characteristics of the final study population
comprising 1560 patients are shown in Table 1. Overall, the
mean age of the group was 59.014.1 years. The majority
(64%) had known or suspected CAD, and a few patients
(n77) had an MI within 7 days before the CMR study. The
mean LVEF was relatively preserved (4518%). The major-
ity (71%) had at least 1 regional wall motion abnormality. HE
was found in 1049 (67%) patients, and for the entire popu-
lation, patients had a median of 4.0 segments with HE
(interquartile range, 0, 9.0). Compared to patients without
HE, patients with HE were older, more often men, and more
likely to have known or suspected heart disease and CAD.
They also were more likely to have a lower LVEF and a
higher wall motion score. Table 1 also shows the baseline
characteristics in the subgroups with and without CAD.
Patients with CAD were older, had lower LVEF, and had
more segments with HE than those without CAD.
Survival Analysis
The median follow-up time was 2.4 years (interquartile range,
1.2, 2.9 years), and the longest follow-up was 5.8 years. A
total of 176 (11.3%) patients died during the follow-up
period. The hazard ratios for all-cause mortality are shown in
Table 2. Patients who died were more likely to be older
(P0.0001), have CAD (P0.004), have lower LVEF
(P0.0001) and higher wall motion score (P0.0001), and
have more segments with HE (P0.0001). In multivariable
Cox regression analysis in which all candidate variables from
univariable analysis were considered, age, LVEF, and the
number of segments with HE were significant independent
predictors of all-cause mortality. We assessed the incremental
predictive value of LVEF and HE by creating 3 different
models: (1) clinical parameters alone, (2) clinicalLVEF,
and (3) clinicalLVEFnumber of HE segments (Table 3).
The addition of LVEF to clinical parameters led to a
significant improvement in the predictive value of the model
as reflected by the increase in global 2 (83.02 versus 126.01,
P0.0001). The addition of segments with HE resulted in
further significant improvement in the model for predicting
all-cause mortality as the 2 increased to 137.87 (P0.001).
Figure 2 illustrates Kaplan–Meier survival curves (adjusted
for age and study site) stratified according to the amount of HE.
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Patients with above-median (4 segments) HE had significantly
reduced survival compared to patients with below- or at-median
(4 segments) HE (P0.002) (Figure 2A). When only patients
with near-normal LVEF (50%) were considered, again, pa-
tients with above-median HE had reduced survival compared to
patients with less HE (P0.02) (Figure 2B).
Given that LVEF was determined by planimetry (n1022;
mean, 44.118.7%) or estimated visually (n538; mean,
47.917.2%) following each site’s institutional protocol,
these subgroups were further evaluated separately. Cox re-
gression analysis showed that the hazard ratio for mortality
by planimetered LVEF (0.965) was nearly identical to that by
visual estimation (0.964) and to the population as a whole
(0.964). Multivariable analysis demonstrated that in the
subgroup with LVEF determined by planimetry, the same
variables were associated with mortality as in the entire
population (Table 2).
Figure 3A details the relationship between categories of
LVEF and all-cause mortality. To account for possible
differences in follow-up time among categories, mortality
rates were calculated for a fixed time point of 2 years for this
analysis. For each decrement in LVEF, there was a steadily
increasing event rate (P0.0001). Likewise, Figure 3B dem-
onstrates that increasing number of segments with HE was
associated with higher mortality rates (P0.0001). However,
the relationship was slightly different from LVEF in that
mortality rates appeared to be similar in groups with 4
segments with HE.
In the cohort of patients with known or suspected CAD
(n1006), again, age, LVEF, and number of segments with
Table 1. Baseline Characteristics and CMR Findings
Characteristic Overall HE HE P
All patients, n 1560 1049 511
Age, y 59.014.1 61.412.3 53.916.2 0.0001
Male sex 1086 (70) 808 (77) 278 (54) 0.0001
Clinical history
Known/suspected heart disease 1465 (94) 1042 (99) 423 (83) 0.0001
Known/suspected CAD 1006 (64) 906 (86) 100 (20) 0.0001
MI within 7 d 77 (5) 76 (7) 1 (0.2) 0.0001
CMR
LVEF, % 45.418.4 38.916.5 58.814.3 0.0001
Any WMA 1111 (71) 982 (94) 129 (25) 0.0001
Wall motion score 0.9 (0, 1.8) 1.4 (0.6, 2.1) 0 (0, 0.1) 0.0001
No. of segments with HE 4.0 (0, 9.0) 7.0 (4.0, 11.0) N/A N/A
Patients with CAD, n 1006 906 100
Age, y 62.711.5 62.311.5 67.010.4 0.0001
Male sex 772 (77) 712 (79) 60 (60) 0.0001
Clinical history
MI within 7 d 77 (8) 76 (9) 1 (1) 0.01
CMR
LVEF, % 39.316.6 37.715.7 54.017.2 0.0001
Any WMA 930 (92) 879 (97) 51 (51) 0.0001
Wall motion score 1.4 (0.6, 2.1) 1.5 (0.8, 2.1) 0.06 (0, 1.0) 0.0001
No. of segments with HE 7.0 (4.0, 11.0) 8.0 (5.0, 11.0) N/A N/A
Patients without CAD, n 554 143 411
Age, y 52.215.8 56.315.5 50.815.7 0.0003
Male sex 314 (57) 96 (67) 218 (53) 0.003
Clinical history
Known/suspected heart disease 459 (83) 136 (95) 323 (79) 0.0001
CMR
LVEF, % 56.416.3 46.119.4 59.913.3 0.0001
Any WMA 181 (33) 103 (72) 78 (19) 0.0001
Wall motion score 0.0 (0, 0.2) 0.4 (0, 1.5) 0 (0, 0.0) 0.0001
No. of segments with HE 0.0 (0, 1.0) 4.0 (2.0, 8.0) N/A N/A
Data are presented as meanSD, n (%), or median (interquartile range), unless otherwise indicated. CAD indicates
coronary artery disease; CMR, cardiovascular magnetic resonance; HE, patients with hyperenhanced tissue on
delayed-enhancement CMR; HE, patients without hyperenhanced tissue on delayed-enhancement CMR; LVEF, left
ventricular ejection fraction; MI, myocardial infarction; N/A, not applicable; WMA, wall motion abnormality.
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HE were significant independent predictors of all-cause
mortality (Table 4). In patients without CAD, age and LVEF
were independent predictors of mortality. Although the num-
ber of segments with HE did not reach statistical significance,
the cohort without CAD comprised a smaller population
(n554), and the hazard ratios for all 3 variables (LVEF, age,
and number of segments with HE) were nearly identical to the
cohort with CAD, suggesting a similar risk for death related
to these parameters in both groups.
Discussion
Recent advances in CMR technology allow a robust, highly
accurate, and reproducible assessment of cardiac function and
myocardial damage within the same examination. Thus,
CMR has become an important noninvasive test for assess-
ment of cardiac patients in clinical routine.35 Published
studies indicate that CMR for detection of MI is accurate36
and provides results equal or superior to radionuclide imag-
ing.23,37 Additionally, CMR is increasingly used for the
evaluation of nonischemic cardiomyopathies and offers
unique diagnostic information on the underlying etiology.38
However, despite the diagnostic utility, few studies have
assessed the prognostic importance of findings on a routine
CMR examination. To our knowledge, the current study is the
largest as well as the first multicenter investigation to
evaluate the prognostic significance of LVEF and myocardial
damage as determined by CMR.
Table 2. HRs for All-Cause Mortality in All Patients and Patients With LVEF as
Determined by Planimetry
Characteristic
All-Cause Mortality
Univariable Multivariable*†
HR (95% CI) P HR (95% CI) P
All patients (n1560)
Clinical
Male sex 1.08 (0.78–1.51) 0.64 0.88 (0.62–1.24) 0.45
Age, y 1.03 (1.02–1.05) 0.0001 1.03 (1.02–1.04) 0.0001
Known/suspected heart disease 2.84 (0.90–8.89) 0.07 1.21 (0.37–3.96) 0.75
Known/suspected CAD 1.71 (1.18–2.47) 0.004 … …
MI within 7 d 0.63 (0.29–1.35) 0.23 … …
CMR
LVEF, % 0.96 (0.95–0.97) 0.0001 0.98 (0.96–0.99) 0.0001
Any WMA 2.54 (1.60–4.02) 0.0001 … …
Wall motion score 1.89 (1.60–2.24) 0.0001 … …
Any HE on DE-CMR 1.69 (1.16–2.46) 0.007 … …
No. of segments with HE 1.007 (1.005–1.009) 0.0001 1.004 (1.002–1.006) 0.0005
Patients with LVEF by planimetry (n1022)
Clinical
Male sex 1.21 (0.79–1.85) 0.39 0.97 (0.63–1.49) 0.89
Age, y 1.04 (1.02–1.05) 0.0001 1.03 (1.01–1.05) 0.0003
Known/suspected heart disease 3.53 (0.49–25,33) 0.21 1.26 (0.17–9.44) 0.82
Known/suspected CAD 1.48 (0.89–2.45) 0.13 … …
MI within 7 d 0.34 (0.08–1.38) 0.13 … …
CMR
LVEF, % 0.97 (0.95–0.98) 0.0001 0.98 (0.96–0.99) 0.002
Any WMA 2.70 (1.39–5.35) 0.004 … …
Wall motion score 1.88 (1.50–2.35) 0.0001 … …
Any HE on DE-CMR 1.54 (0.93–2.56) 0.09 … …
No. of segments with HE 1.007 (1.005–1.009) 0.0001 1.004 (1.002–1.007) 0.001
DE indicates delayed enhancement; HR, hazard ratio. Other abbreviations as in Table 1.
*Multivariable analysis adjusted for study site.
†Collinear variables were not included in the multivariable analyses.
Table 3. Incremental Prognostic Value of LVEF and Number of
Segments With HE (All Patients)*
All-Cause Mortality
Model Model 2 Change in 2 P
Clinical 83.02 … …
Clinical with LVEF 126.01 42.99 0.0001
Clinical with LVEF and No. of
segments with HE
137.87 11.86 0.001
Abbreviations as in Table 1.
*All models were adjusted for study site.
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Several studies have established that LVEF is a strong
predictor of adverse outcome in various patient cohorts.5,6,8
Previous investigations ascertaining the prognostic impor-
tance of LVEF used established imaging modalities, such as
echocardiography,5,7,9,39 radionuclide ventriculography,6,10
and ECG-gated single-photon emission CT,11 and generally
included large numbers of patients. Among the largest studies
investigating the prognostic value of LVEF determined by
ECG-gated single-photon emission CT was that by Travin et
al11 of 3207 patients. Using echocardiography, Gottdiener et
al39 investigated the relationship of LVEF and mortality in
5532 patients, whereas Zaret et al10 included 3197 patients in
whom LVEF was measured with radionuclide ventriculogra-
phy. Curtis et al6 investigated the relationship between LVEF
measurements by echocardiography and radionuclide or con-
trast ventriculography and mortality in 7788 patients. Al-
though CMR allows the determination of LVEF with superior
precision and reproducibility, agreement of LVEF measure-
ments among different modalities used in the same patient is
moderate at best.19 Therefore, the relationship between CMR-
determined LVEF and mortality requires separate evaluation.
To date, the largest published CMR studies evaluating prog-
nosis were single-center investigations involving 513 pa-
tients40 and 857 patients.16 The present multicenter study in
1560 patients corroborates those previous reports in that
CMR-determined LVEF was found to be an important pre-
dictor of adverse outcome.
Additionally, the current results suggest that the associa-
tion between LVEF and mortality holds across the full
spectrum of LVEF. This is in contrast to some studies where
higher LVEF values were associated with a linear decrease in
mortality up to an LVEF of 45%, but further increases in
LVEF above this point were not associated with further
reductions in mortality.6 The possible difference in findings
may be due to dissimilarities in the patient population. In the
current study, a broad spectrum of patients with known or
suspected heart disease presenting for routine CMR imaging
were included, and there was a nearly 5-fold difference in
mortality between patients in the lowest and highest LVEF
groups. In the investigation by Curtis et al,6 enrollment was
restricted to stable outpatients given a clinical diagnosis of
heart failure, and there was only a 2.2-fold relative difference
Figure 2. Kaplan–Meier estimates of survival. Survival curves in all patients (A) and in patients with LVEF 50% (B) stratified according
to the amount of HE (adjusted for age and study site). In both the entire group and the patients with near-normal LVEF, those with
above-median HE (4 segments) had reduced survival compared with patients with below- or at-median HE (4 segments). HE indi-
cates hyperenhanced tissue; LVEF, left ventricular ejection fraction.
Figure 3. Mortality rate as a function of LVEF and amount of myocardial damage. The height of the bar and the number within repre-
sent the observed mortality rate at 2 years and total number of subjects for each category of LVEF (A) and HE (B). Solid lines represent
Cox regression estimates (smoothed) of 2-year mortality adjusted for age and study site. Dashed lines represent 95% CIs. With each
decrement in LVEF, there was a steadily increasing mortality rate. Likewise, increasing number of segments with HE was associated
with higher mortality rates, although rates appeared to be similar in groups with 4 segments of HE. Abbreviations as in Figure 2.
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in mortality rates. Moreover, in the study by Curtis et al,
neither the technique (echocardiography, equilibrium radio-
nuclide angiography, or contrast ventriculography was used)
nor interpretation of LVEF measurement was standardized.
In addition to the accurate assessment of LVEF, CMR
provides high-resolution images of irreversible myocardial
damage.12,27,41 Of the studies that have assessed the prognos-
tic importance of CMR-identified myocardial dam-
age,12,13,15,42–44 none were multicenter, and in most, the
primary end point was a composite, including “softer” events
such as hospitalizations, occurrence of arrhythmias, and
MI.12,18,42 Only a few studies used all-cause mortality as a
primary end point. Yan et al15 demonstrated in 144 patients
with prior MI that certain infarct characteristics (ie, extent of
periinfarct zone) on DE-CMR predicted all-cause mortality
independent of age and LVEF. Kim et al17 studied patients
with suspected CAD and without a history of clinical MI. The
presence of unrecognized non-Q-wave MI on DE-CMR was
associated with an 11-fold higher mortality rate. In the largest
study to date assessing the prognostic significance of DE-
CMR, Cheong et al16 evaluated 857 patients from a tertiary-
care center and demonstrated that a myocardial scar index
independently predicted all-cause mortality or cardiac trans-
plantation. The results of the present multicenter study are
consistent with these prior investigations. Moreover, similar
to the study by Cheong et al, we found that even in patients
with near-normal LVEF (50%) the presence of substantial
myocardial damage identifies a cohort with increased risk for
all-cause mortality. Thus, CMR may be a useful risk stratifi-
cation tool in patients generally considered to be at low risk
based on LVEF criteria.
Several possible mechanisms have been proposed in linking
myocardial damage and increased mortality. Experimental stud-
ies have shown that abnormal conduction properties within or
surrounding myocardial scar are critical for reentry circuits to
form, which are believed to be an important electrophysiological
substrate for ventricular tachyarrhythmias45–47 and sudden car-
diac death.48 Initial studies have shown that DE-CMR may be
helpful in identifying patients at risk for ventricular tachycardia
among those with prior infarcts43,44 as well as nonischemic
cardiomyopathy.12,13 These investigations suggest a potential
role of DE-CMR in risk stratification for cardiac arrhythmias
and sudden death as well as for selection of patients for
implantable cardioverter-defibrillator therapy.
Limitations
Enrollment was prospective in 2 centers and retrospective in
8. Clinical variables such as the presence of CAD were
obtained by review of medical records by local site investi-
gators but did not require specific test results to be submitted
to the DCC. The findings on routine CMR were not compared
Table 4. HRs for All-Cause Mortality in Subgroups
Characteristic
All-Cause Mortality
Univariable Multivariable*†
HR (95% CI) P HR (95% CI) P
Patients with CAD (n1006)
Clinical
Male sex 0.91 (0.62–1.33) 0.62 0.83 (0.56–1.23) 0.35
Age, y 1.04 (1.02–1.05) 0.0001 1.03 (1.02–1.05) 0.0001
MI within 7 d 0.55 (0.26–1.18) 0.13 … …
CMR
LVEF, % 0.96 (0.95–0.97) 0.0001 0.97 (0.96–0.99) 0.0003
Any WMA 1.90 (0.78–4.66) 0.16 … …
Wall motion score 1.98 (1.57–2.48) 0.0001 … …
Any HE on DE-CMR 1.03 (0.57–1.86) 0.93 … …
No. segments with HE 1.007 (1.005–1.009) 0.0001 1.005 (1.002–1.007) 0.0001
Patients without CAD (n554)
Clinical
Male sex 1.19 (0.61–2.32) 0.62 0.97 (0.48–1.97) 0.93
Age, y 1.02 (1.00–1.05) 0.03 1.02 (1.00–1.05) 0.047
CMR
LVEF, % 0.97 (0.96–0.99) 0.001 0.97 (0.96–0.99) 0.01
Any WMA 2.55 (1.32–4.95) 0.006 … …
Wall motion score 1.78 (1.27–2.49) 0.0009 … …
Any HE on DE-CMR 1.93 (0.99–3.75) 0.052 … …
No. segments with HE 1.007 (1.003–1.012) 0.002 1.003 (0.997–1.009) 0.29
Abbreviations as in Tables 1 and 2.
*Multivariable analysis adjusted for study site.
†Collinear variables were not included in the multivariable analysis.
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to a comprehensive list of traditional clinical risk factors
known to be associated with adverse outcome because data
collection was limited to a few prespecified variables. Like-
wise, we do not have quantitative measures of cardiac
morphology, such as LV end-diastolic and end-systolic vol-
umes. However, we demonstrated in a relatively large study
population that myocardial hyperenhancement (indicating
damage) has prognostic importance independent of LVEF,
which is believed to be one of the strongest and most robust
predictors of mortality. We did not ascertain the cause of
death, and the primary end point was chosen to be all-cause
rather than cardiac mortality. However, many believe that the
most appropriate end point is total mortality (recommended
by a policy statement written by the North American Society
for Pacing and Electrophysiology49) because it is objective,
clinically relevant, and unbiased, which often is not the case
for cardiac mortality.50 We did not collect data regarding the
clinical indications for CMR, which limits our ability to
generalize the findings to other cohorts. However, patients
were consecutively enrolled from 10 busy CMR centers
across Europe, the United States, and Brazil; the inclusion
criteria (Figure 1) were broad; and the sample size was
relatively large. Hence, we believe that the patient cohort is
likely to be reflective of the current real-life clinical practice
of CMR. On this issue, it is informative that a recent
multicenter study (using many of the same CMR centers as
the present study) reported the most common indications for
CMR were evaluation of cardiomyopathy/myocarditis (32%),
risk stratification in suspected coronary disease (31%), and
assessment of viability (15%).35 In one third of patients,
LVEF was assessed visually. However, because the same
process used for routine clinical interpretations was followed
at each site, this again reflects the real-life clinical practice of
CMR. Moreover, the results (Figure 3A) clearly demonstrate
a steadily increasing event rate with each decrement in LVEF,
suggesting that the main conclusions would not be substan-
tially changed if all studies had been assessed quantitatively.
The presence and extent of HE was interpreted qualitatively
by different readers at each site. Although all sites used a
standard 17-segment and 5-point scoring model,36 we found
that some centers scored hyperenhancement based on the
maximum transmural extent at any given point in the segment
rather than the area of hyperenhancement within the segment.
This precluded calculating the amount of HE as a percentage
of LV mass as described previously,17 and the absolute
inflection point at which an increase in mortality risk occurs
could not be accurately determined in this study. However,
the principal relationship between HE and mortality could be
established. We did not differentiate CAD-type hyperen-
hancement from other non-CAD-type patterns. Although both
have been shown to be associated with adverse events, there
may be differences in the prognostic importance between
damaged tissue from MI or nonischemic heart diseases.
Similarly, although our results demonstrate that lower LVEF
(compared with higher LVEF) and more HE (compared with
less HE) portend worse prognosis, one should not assume that
LVEF or hyperenhancement has a uniform effect on mortality
across the cardiac disorders included in the current broad
population. Finally, there could be a potential bias in the
estimated mortality rates because patients were not censored
during year 1 except for those who died.
Conclusions
In patients undergoing a routine CMR study, including cine
and delayed-enhancement imaging, both LVEF and the
amount of myocardial tissue damage are independent predic-
tors of all-cause mortality. Furthermore, even in patients with
near-normal LVEF who generally are considered to be at low
risk, significant myocardial damage identified a cohort with
significantly worse prognosis. These findings warrant future
studies to investigate the role of CMR in clinical management
decisions based on risk stratification.
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CLINICAL PERSPECTIVE
Cardiac magnetic resonance (CMR) is considered the reference standard for assessment of left ventricular ejection fraction
(LVEF) and myocardial damage. However, few studies have evaluated the relationship between CMR findings and patient
outcome, and of these, most are small and none multicenter. We performed an international, multicenter study to assess
the prognostic importance of routine CMR in patients with known or suspected heart disease. Consecutive patients from
10 centers in 6 countries who underwent routine CMR assessment of LVEF and myocardial damage by cine- and
delayed-enhancement CMR, respectively, were screened. A total of 1560 patients were enrolled (age, 5914 years; 70%
men). Mean LVEF was 4518%, and 1049 (67%) patients had hyperenhanced tissue on delayed-enhancement CMR
indicative of damage. During a median follow-up time of 2.4 years, 176 (11.3%) patients died. Patients who died were more
likely to be older, have coronary artery disease, have lower LVEF, and have more segments with hyperenhanced tissue.
In multivariable analysis, age, LVEF, and number of segments with hyperenhanced tissue were independent predictors of
mortality. The number of segments with hyperenhanced tissue provided incremental prognostic value beyond clinical data
and LVEF. Even in patients with near-normal LVEF, significant damage identifies a cohort at high risk for early mortality.
In this study, we demonstrated that in a large population from several CMR centers, unique CMR information on
myocardial damage from ischemic and nonischemic etiologies provides independent and incremental prognostic value.
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